JENA (dpa-AFX) - Carl Zeiss Meditec AG (CZMWF.PK) said it expects its financial result to be burdened by an impairment of the investment in Oraya Therapeutics Inc. of around 20 million euros.
Oraya Therapeutics markets a radiotherapy for wet, age-related macular degeneration in the United Kingdom, Germany and Switzerland.
Carl Zeiss Meditec has provided funds used for further expansion of the business of Oraya under an agreement concluded in December 2014.
Progress has been made in commercializing the therapy during the year. However, there has been a significant deviation from the original business plan, so that an adjustment of the book value of the investment is necessary.
Copyright RTT News/dpa-AFX